Saphnelo

(anifrolumab-fnia)
Saphnelo 300 MG in 2 ML Injection
NO BOXED WARNING

Dosage & administration

The recommended dosage is 300 mg as an intravenous infusion over a 30‑minute period every 4 weeks. For complete dilution and intravenous administration instructions see Full Prescribing Information.

drug label

Saphnelo prescribing information

prior authorization

Saphnelo prior authorization resources

Most recent Saphnelo prior authorization forms

View By Payer
Verified: Feb 07, 2024Kaiser Foundation Health Plan - Chronic High-Dose Opioid Therapy Prior Authorization Form Washington
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Medical Injectable Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Outpatient Chemotherapy Prior Authorization Form (Medical Benefit)
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Specialty Drug Prior Authorization Form
Verified: Feb 01, 2024Highmark BCBS Northeastern NY - Non-Formulary Drug Coverage Prior Authorization Form

Most recent state uniform prior authorization forms

Verified: Jan 28, 2024Oregon - Uniform Prior Authorization Form
Verified: Jan 28, 2024Colorado - Uniform Prior Authorization Form
Verified: Jan 28, 2024Michigan - Uniform Prior Authorization Form
Verified: Jan 28, 2024Hawaii - Uniform Prior Authorization Form
Verified: Jan 28, 2024Minnesota - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Jan 28, 2024New Mexico - Uniform Prior Authorization Form
Verified: Jan 28, 2024Texas - Uniform Prior Authorization Form
Verified: Jan 28, 2024Louisiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Arizona - Uniform Prior Authorization Form
Verified: Jan 28, 2024Indiana - Uniform Prior Authorization Form
Verified: Jan 28, 2024Illinois - Uniform Prior Authorization Form
Saphnelo Supports Access 360 Enrollment Form
Saphnelo Supports Access 360 Enrollment Form - Spanish
Patient Authorization Form
Learn More

Benefits investigation

Saphnelo Supports Access 360 Enrollment Form
Saphnelo Supports Access 360 Enrollment Form - Spanish
Patient Authorization Form
Learn More

Reimbursement help (FRM)

Receive Assistance from an FRM Regarding Reimbursement Information
Learn More

pharmacy

Saphnelo preferred pharmacy

Pharmacy List

financial assistance

Saphnelo financial assistance options

Co-pay savings program

commercial only
Saphnelo Supports Access 360 Enrollment Form
Saphnelo Supports Access 360 Enrollment Form - Spanish
Patient Authorization Form
Enroll in Patient Savings Program
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
Patient Authorization Form
Learn More

PubMed™ | Saphnelo

Saphnelo PubMed™ News

patient education

Saphnelo patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Saphnelo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Receiving Saphnelo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Copay Savings Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Saphnelo Supports Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Saphnelo Supports Brochure: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Treatment Roadmap
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Treatment Roadmap: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Infusion Preparation Tips
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Infusion Preparation Tips: Spanish
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Saphnelo FAQs

Is SAPHNELO safe to use during pregnancy?The limited human data with SAPHNELO use in pregnant women are insufficient to inform on drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcome. Monoclonal IgG antibodies are known to be actively transported across the placenta as pregnancy progresses; therefore, anifrolumabfnia exposure to the fetus may be greater during the third trimester of pregnancy. A pregnancy exposure registry monitors pregnancy outcomes in women exposed to SAPHNELO during pregnancy. Pregnant women with SLE are at increased risk of adverse pregnancy outcomes. If you are pregnant and taking SAPHNELO, contact AstraZeneca at 1-877-693-9268.
What is the risk of birth defects and miscarriage with SAPHNELO use during pregnancy?The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Can SAPHNELO be used during lactation?No data are available regarding the presence of SAPHNELO in human milk, the effects on the breastfed child, or the effects on milk production. Anifrolumab-fnia was detected in the milk of female cynomolgus monkeys administered anifrolumab-fnia. If you are breastfeeding while taking SAPHNELO, consult with your healthcare provider to assess the potential risks and benefits.
Is SAPHNELO safe for use in pediatric patients?The safety and efficacy of SAPHNELO in pediatric patients less than 18 years of age have not been established.
Is SAPHNELO safe for use in geriatric patients?Of the 664 patients with SLE exposed to anifrolumab-fnia in clinical trials, 3% (n=20) were 65 and over. The number of patients aged 65 years of age and older was not sufficient to determine whether they respond differently from younger adult patients.
FAQ Data Source